N/A
Manufactured by Actavis Pharma, Inc.
7,483 FDA adverse event reports analyzed
Last updated: 2026-04-15
PERPHENAZINE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Actavis Pharma, Inc.. The most commonly reported adverse reactions for PERPHENAZINE include DRUG INEFFECTIVE, TOXICITY TO VARIOUS AGENTS, WEIGHT INCREASED, AKATHISIA, SUICIDE ATTEMPT. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for PERPHENAZINE.
Out of 2,013 classified reports for PERPHENAZINE:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 7,483 FDA FAERS reports that mention PERPHENAZINE. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include DRUG INEFFECTIVE, TOXICITY TO VARIOUS AGENTS, WEIGHT INCREASED, AKATHISIA, SUICIDE ATTEMPT, OFF LABEL USE. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Actavis Pharma, Inc. in connection with PERPHENAZINE. Always verify the specific product and NDC with your pharmacist.